Promising Three-Drug cocktail targets Hard-to-Treat leukemia
NCT ID NCT07486726
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of three drugs—aclarubicin, azacitidine, and venetoclax—in people with acute myeloid leukemia (AML) who are either newly diagnosed and unable to tolerate standard chemotherapy, or whose cancer has returned or not responded to treatment. The trial has two phases: first, to find the safest dose of aclarubicin, and second, to see how well the combo works at achieving remission. Up to 112 adults will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aclarubicin (a chemotherapy drug) combined with azacitidine and venetoclax
What this could lead to
If successful, this could offer a new treatment option for AML patients who cannot tolerate standard intensive chemotherapy, potentially improving remission rates.
What could go wrong
This is an early phase 1/2 trial with only 112 participants, so results are preliminary. The combination may cause side effects or fail to work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Jing'an District Beizhan Hospital
Shanghai, China
Contact Phone: •••-•••-••••
-
Shanghai Traditional Chinese Medicine Hospital
Shanghai, China
Contact Email: •••••@•••••
-
Tongren Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••